Risk of Alzheimer's disease among users of postmenopausal hormone therapy: A nationwide case-control study
- PMID: 28274328
- DOI: 10.1016/j.maturitas.2017.01.002
Risk of Alzheimer's disease among users of postmenopausal hormone therapy: A nationwide case-control study
Abstract
Objective: To examine the association between postmenopausal hormone therapy (HT) and Alzheimer's disease (AD).
Methods: Medicine and Alzheimer's disease (MEDALZ) is a nested case-control study of the entire Finnish population with clinically verified AD from 2005 to 2011 and up to 4 matched controls per case. This study comprises 230,580 women (46,117 cases and 184,463 controls). Data on HT use from 1995 to 2011 was extracted from the national prescription register using following ATC codes: G03C (estrogen), G03D (progestogen) and G03F (estrogen and progestogen in combination). Only systemic HT (oral or transdermal) was considered.
Results: Use of systemic estrogen and progestogen was associated with an increased risk of AD, with ORs (95% CI) of 1.10 (1.06-1.12) and 1.13 (1.10-1.17) respectively, but use of systemic estrogen HT for >10years (OR, 95% CI: 0.91, 0.84-0.99) was protective against AD. Long-term (>10years) use of progestogen and combination HT was not related to AD risk (OR, 95% CI: 1.0, 0.90-1.2).
Conclusion: Our findings do not suggest HT is an important determinant of AD risk.
Keywords: Alzheimer’s disease; Estrogen; Gynecological surgery; Hormone therapy; Menopause; Progestogen.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
-
Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study.BMJ. 2019 Mar 6;364:l665. doi: 10.1136/bmj.l665. BMJ. 2019. PMID: 30842086 Free PMC article.
-
Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration.Menopause. 2016 Jun;23(6):593-9. doi: 10.1097/GME.0000000000000611. Menopause. 2016. PMID: 27023862
-
Transdermal hormone therapy and the risk of stroke and venous thrombosis.Climacteric. 2010 Oct;13(5):429-32. doi: 10.3109/13697137.2010.507111. Climacteric. 2010. PMID: 20670199
-
Estrogen and progestogen effect on venous thromboembolism in menopausal women.Climacteric. 2012 Jun;15(3):235-40. doi: 10.3109/13697137.2012.664401. Climacteric. 2012. PMID: 22612609 Review.
-
Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis.Climacteric. 2018 Aug;21(4):341-345. doi: 10.1080/13697137.2018.1446931. Epub 2018 Mar 23. Climacteric. 2018. PMID: 29570359 Review.
Cited by
-
Estradiol enhanced neuronal plasticity and ameliorated astrogliosis in human iPSC-derived neural models.Regen Ther. 2024 Jan 12;25:250-263. doi: 10.1016/j.reth.2023.12.018. eCollection 2024 Mar. Regen Ther. 2024. PMID: 38293585 Free PMC article.
-
Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer's disease and dementia.Front Aging Neurosci. 2023 Oct 23;15:1260427. doi: 10.3389/fnagi.2023.1260427. eCollection 2023. Front Aging Neurosci. 2023. PMID: 37937120 Free PMC article.
-
The role of oestrogen therapy in reducing risk of Alzheimer's disease: systematic review.BJPsych Open. 2023 Oct 17;9(6):e194. doi: 10.1192/bjo.2023.579. BJPsych Open. 2023. PMID: 37846476 Free PMC article. Review.
-
Ageing perspective on cognitive outcomes from reproductive hormone adjustments.Heliyon. 2023 Aug 16;9(8):e19050. doi: 10.1016/j.heliyon.2023.e19050. eCollection 2023 Aug. Heliyon. 2023. PMID: 37664737 Free PMC article. Review.
-
[Cognitive and psychoemotional changes in menopausal transition: The possibility of medical correction].Probl Endokrinol (Mosk). 2023 Feb 25;69(1):86-95. doi: 10.14341/probl13205. Probl Endokrinol (Mosk). 2023. PMID: 36842081 Free PMC article. Russian.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
